Zacks: Brokerages Expect Metlife Inc (NYSE:MET) to Post $1.61 Earnings Per Share

Wall Street brokerages expect Metlife Inc (NYSE:MET) to post earnings per share of $1.61 for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Metlife’s earnings, with estimates ranging from $1.53 to $1.69. Metlife reported earnings of $1.27 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.8%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 4th.

According to Zacks, analysts expect that Metlife will report full-year earnings of $5.54 per share for the current fiscal year, with EPS estimates ranging from $5.40 to $5.67. For the next year, analysts forecast that the business will report earnings of $6.19 per share, with EPS estimates ranging from $6.05 to $6.40. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Metlife.

Metlife (NYSE:MET) last issued its earnings results on Wednesday, August 5th. The financial services provider reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.07). Metlife had a return on equity of 7.71% and a net margin of 10.65%.

A number of equities research analysts recently weighed in on MET shares. Wells Fargo & Company restated a “buy” rating and issued a $45.00 price target on shares of Metlife in a report on Thursday, August 6th. Morgan Stanley increased their target price on Metlife from $44.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Zacks Investment Research upgraded Metlife from a “sell” rating to a “hold” rating and set a $45.00 target price on the stock in a report on Tuesday, June 9th. Argus reiterated a “buy” rating on shares of Metlife in a report on Wednesday, August 19th. Finally, Bank of America initiated coverage on Metlife in a report on Monday, June 1st. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $42.25.

In related news, Director Catherine R. Kinney sold 3,657 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $39.50, for a total value of $144,451.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.07% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Two Sigma Advisers LP raised its position in shares of Metlife by 92.3% in the 2nd quarter. Two Sigma Advisers LP now owns 557,199 shares of the financial services provider’s stock worth $20,349,000 after buying an additional 267,500 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its position in Metlife by 6.0% in the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 1,105,517 shares of the financial services provider’s stock valued at $40,373,000 after purchasing an additional 62,635 shares during the period. Principal Financial Group Inc. raised its position in Metlife by 2.1% in the second quarter. Principal Financial Group Inc. now owns 1,126,085 shares of the financial services provider’s stock valued at $41,125,000 after purchasing an additional 22,790 shares during the period. Bridgeway Capital Management Inc. raised its position in Metlife by 3.5% in the second quarter. Bridgeway Capital Management Inc. now owns 777,500 shares of the financial services provider’s stock valued at $28,394,000 after purchasing an additional 25,950 shares during the period. Finally, Lumbard & Kellner LLC raised its position in Metlife by 0.3% in the second quarter. Lumbard & Kellner LLC now owns 140,147 shares of the financial services provider’s stock valued at $5,118,000 after purchasing an additional 470 shares during the period. 74.92% of the stock is currently owned by institutional investors and hedge funds.

Shares of MET traded up $0.12 on Wednesday, reaching $37.63. The stock had a trading volume of 8,554,093 shares, compared to its average volume of 6,760,743. The firm has a market capitalization of $34.16 billion, a PE ratio of 4.89, a PEG ratio of 2.21 and a beta of 1.30. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average of $38.52 and a 200 day moving average of $35.84. Metlife has a twelve month low of $22.85 and a twelve month high of $53.28.

The company also recently announced a quarterly dividend, which was paid on Monday, September 14th. Investors of record on Tuesday, August 4th were given a $0.46 dividend. This represents a $1.84 annualized dividend and a dividend yield of 4.89%. The ex-dividend date was Monday, August 3rd. Metlife’s dividend payout ratio (DPR) is currently 30.11%.

About Metlife

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

See Also: Strangles

Get a free copy of the Zacks research report on Metlife (MET)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with's FREE daily email newsletter.